Its two leading candidates, TERN-601 and TERN-501 -- both in the anti-obesity field -- are close to entering phase 2 studies. The stock's returns in the next few years will depend on clinical and ...

Additionally, we are pleased to announce that the first patient has been enrolled in the FALCON trial of TERN-601, with 12-week data also expected in the fourth quarter. We continue to operate ...

Dose expansion in Phase 1 CARDINAL trial of TERN-701 for chronic myeloid leukemia (CML) expected to initiate in 2Q25 with additional safety and efficacy data in 4Q25 First patient enrolled in Phase 2 ...